- Digital Health
Amphivena Therapeutics, Inc. is a private immuno-oncology company that is developing selective T cell engagers for the treatment of hematologic and solid tumors. AMV564, our lead molecule, has demonstrated novel clinical activity by rapidly and selectively eliminating leukemic blasts and immature, granulocytic and monocytic myeloid derived suppressor cells (MDSC) while sparing normal myeloid cells, including neutrophils and monocytes. AMV564 has an excellent safety profile that enables competitive approaches, including combination therapy, and provides a unique opportunity to explore the impact of MDSC depletion in cancer.
South San Francisco, CA
ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary products that activate the immune system of cancer patients to recognize and eradicate tumors. In May 2018, Eli Lilly and Company (NYSE: LLY) and ARMO BioSciences, Inc. (NASDAQ: ARMO) announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion, in an all-cash transaction.
Redwood City, CA
Cadent Therapeutics is rapidly advancing a pipeline of novel allosteric modulators of ion channels – taking a well-established pharmaceutical approach and stepping out into new territory. SK channels and NMDA receptors are ion channels that are critical for modulating the strength, timing, and integration of communication between and within neurons and neuronal networks in the central nervous system.
Cardialen is developing an implantable defibrillator using low-electrical energy to restore normal heart rhythm and potentially avoid the negative side-effects of current therapies.
Element Science is an innovative San Francisco-based medical device and digital health company focused on developing solutions at the intersection of clinical-grade wearable devices, machine learning algorithms and lifesaving therapies to address the needs of high-risk cardiovascular patients, primarily as they transition from the hospital to home.
The company was founded in 2011 by Uday Kumar, MD, a cardiac electrophysiologist by training, and founder of iRhythm Technologies (NASD: IRTC), a leading digital healthcare company focused on cardiac rhythm diagnosis.
Element Science is developing a proprietary next-generation wearable digital platform that unites patient centric human factor engineering, sophisticated machine learning algorithm development principles, and rigorous electromechanical medical device development standards. The platform will address leading causes of death and hospitalization due to heart disease. The first product, an unobstructive, low-profile personal wearable defibrillator, aims to redefine the treatment for temporary periods of elevated Sudden Cardiac Death (SCD) risk.
Elevation Oncology is focused on identifying and targeting inhibition of each tumor’s specific driver alterations. Delivering improved care and outcomes for patients. Their combined efforts, as part of a vibrant precision medicine community, enables the development of a personalized treatment plan for each individual cancer patient.
Icosavax is committed to developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. We were founded on breakthrough computationally-designed virus-like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington.
Jasper Therapeutics is enabling cures through stem cell transplantation. The company is testing a c-Kit/ CD119 antibody (JSP-191) which is currently in late-stage clinical testing for Hematopoietic Cell Transplantation (HCT) associated with Severe Combined Immunodeficiency and MDS/AML. The humanized monoclonal antibody creates a niche space in the bone marrow by safely and specifically targeting and depleting blood forming stem cells and progenitor cells. Jasper intends to license JSP-191 for gene and cell therapy preconditioning regimes. Jasper was founded out of Stanford and JSP-191 was invented and developed at Amgen.
Kezar Life Sciences (NASDAQ: KZR) is a clinical-stage biotechnology company, discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. Our lead product candidate, KZR-616, a first-in-class selective immunoproteasome inhibitor, has completed testing in healthy volunteers and is now enrolling a Phase 1b/2 clinical trial in lupus and lupus nephritis.
South San Francisco, CA
KORRO BIO is an early stage company creating transformative therapeutics for patients by selectively editing messenger RNA to recode specific codons to deliver a beneficial change in protein sequence, structure and function.
LetsGetChecked is all about personal health testing, making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple but powerful way and giving greater control of their personal health.
New York, NY
Madaket automates the manual, error-prone process of enrolling in Electronic Funds Transfer (EFT), Electronic Remittance Advice (ERA), Electronic Data Interchange for Claims (EDI) and other common provider-payer transactions. The result is less paperwork and faster payments for hospitals, health systems, and private practices.
MyHealthTeams creates social networks for communities of people facing chronic conditions (everything from Lupus and multiple sclerosis, to autism, breast cancer, and COPD). We believe that when people facing the same chronic condition are able to connect with and learn from each other, ask questions, get referrals and share tips with other people who personally understand what it’s like to face that condition, health outcomes improve.
San Francisco, CA
Nuvaira, Inc. is a privately held medical device company that develops minimally invasive products to make breathing easier for patients suffering from obstructive lung diseases. Specifically, the company has developed a novel, catheter-based system to address chronic obstructive pulmonary disease (COPD) and asthma by treating the overactive airway nerves in a procedure called Targeted Lung Denervation (TLD). Nuvaira received CE Mark approval for its Nuvaira™ Lung Denervation System in January 2016.
Platelet BioGenesis is a Harvard University spinout that is making human platelets from stem cells. We have developed and patented a microfluidic bioreactor, and shown that functional platelets can be generated from human pluripotent stem cell cultures. By removing the volunteer donor, we can make platelets that are cheaper, safer, and available on demand.
Talaris is developing a single-dose cell therapy that seeks to free organ transplant recipients of the burdens and toxicities of lifelong immunosuppression, without rejecting their transplanted organ.
The Twine Health platform brings a scalable approach to health coaching, allowing a single coach to work with a large number of patients, driving efficiencies while helping more people reach their goals. In February 2018, Fitbit, Inc. (NYSE: FIT) the leading global wearables brand, announced that it will acquire Twine Health.
WindMIL harnesses the power of bone marrow derived lymphocytes to develop ground-breaking immunotherapies to treat cancer patients. Our lead program is in a Phase 2b study in high-risk multiple myeloma with additional programs in solid tumors using MILsTM advancing to the clinic. We are also advancing programs to supercharge MILs through genetic-modification.
ZappRx is a digital health company offering a prescription and prior authorization (“PA”) platform; our goal is to streamline and increase efficiencies in the way specialty medications reach patients. We provide a secure, collaborative online platform that allows patients, physicians, and pharmacists to work together to improve patients’ access to treatment and deliver medicine faster.